Eli Lilly & Co. (NYSE:LLY)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.

Recs

0
Player Avatar GETRICHSLOW2 (69.51) Submitted: 12/12/2011 10:16:26 PM : Outperform Start Price: $38.11 LLY Score: +2.06

Falling off the patent cliff but the metrics look outstanding. A great time to buy in. Company has been around since 1901. I doubt they will go under just because of a few patent expirations. Currently yielding 5%. p/e=8.5, payout ratio=43%, beta= 0.67.

Buy Buy Buy!

Featured Broker Partners


Advertisement